Immuno Lab · DeCure for X
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for systemic lupus erythematosus — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for systemic lupus erythematosus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
complement C1q B chain (C1QB) — C1QB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 2WNV · 1.25 Å · ligand 2-deoxy-beta-D-erythro-pentofuranose (2DR). Experimental structure, not a prediction.
Six female patients with systemic lupus erytheosus and nephrotic syndrome refractory to immunosuppressive drugs received 15–20 exchange plasmaphereses. One patient treated concurrently with high-dose steroids showed temporary improvement. Five patients treated concurrently with steroids and either cyclophosphamide or azathioprine had long-term remissions. The authors called plasmapheresis a promising modality in refractory lupus nephritis with nephrotic syndrome. No control group was included, and the sample size is six.
A 2004 review notes that systemic lupus erythematosus represents a clinical syndrome rather than a unique disease entity, with pathogenic mechanisms that vary among individual patients. The disease phenotype arises from a variable mixture of environmental factors, hormonal milieu, and genetic contributions to an autoimmune diathesis. The review does not report any trial results or survival data.
A 2015 review states that the precise pathogenic mechanism of lupus remains uncertain but involves activation and deregulation of many immune system components. Certain patterns of immune pathology are shared by a significant subset of patients, and selective targeting of key immune molecules offers the prospect of more effective treatment. The review discusses recent clinical trials with biological agents but does not provide concrete numbers for any drug’s efficacy or survival.
What is still missing: large randomised controlled trials for plasmapheresis in lupus nephritis, a clear patient stratification strategy to match the variable pathogenic mechanisms described, and funding to test whether the immune targets identified in pathophysiology translate into durable clinical responses.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractDapsone 100 mg daily led to a rapid and complete clearing of extensive vasculitic urticarial lesions in a female patient with systemic lupus erythematosus. Complement determinations revealed an intensive activation of the classical pathway before dapsone therapy. Normalization of CH50, C1 and C2 occurred during the treatment, whereas C3 and C4 remained lowered.
https://doi.org/10.1159/000250270AbstractFrom a historical perspective, there are few diseases for which the cause, natural history, and response to treatment have been as complex or difficult to define as those of systemic lupus erythematosus (SLE). In large part, this is because SLE represents a clinical syndrome rather than a unique disease entity. The apparent diversity of pathogenic mechanisms operating in individual patients, which parallels the diversity observed in various animal models of SLE, underscores the fact that the disease phenotype arises from a variable mixture of environmental factors, the hormonal milieu, genes that contribute to an autoimmune diathesis, and other causes of . . .
https://doi.org/10.1056/nejme048010AbstractLupus nephritis with nephrotic syndrome is one of the most serious complications of systemic lupus erythematosus. Six female patients with systemic lupus and nephrotic syndrome, refractory to immunosuppressive drug therapy, received 15-20 exchange plasmaphereses. One patient, treated concurrently with high-dose steroids, showed temporary improvement, and five patients, treated concurrently with steroids and either cyclophosphamide or azathioprine, had long-term remissions. Plasmapheresis is a promising therapeutic modality in cases of refractory lupus nephritis with nephrotic syndrome.
https://doi.org/10.1002/jca.2920010109AbstractSystemic lupus erythematosus is an autoimmune disorder that can affect every organ system and cause a wide range of signs and symptoms. The precise pathogenic mechanism of disease remains uncertain, but it is clearly complex and involves the activation and deregulation of many components of the immune system. Certain well-characterized patterns of immune pathology are shared by a significant subset of patients and selective targeting of one or more of the key immune system molecules offers the prospect of more effective treatment. This review addresses the current and future treatment for patients with lupus, going from the lessons learnt with pathophysiologic studies to recent clinical trials with biological agents.
https://doi.org/10.1586/1744666x.2015.1078237Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
